Gabelli Funds’s Teva Pharmaceuticals TEVA Stock Holding History

Gabelli Funds’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.2M	Sell	331,500 -1,400	-0.4%	-$46.6K	0.07%	318
2026 Q1	$10M	Sell	332,900 -23,700	-7%	-$762K	0.07%	329
2025 Q4	$11.1M	Sell	356,600 -85,075	-19%	-$2.1M	0.08%	297
2025 Q3	$8.92M	Buy	441,675 +200	+0%	+$3.51K	0.06%	347
2025 Q2	$7.4M	Buy	441,475 +6,400	+1%	+$103K	0.05%	382
2025 Q1	$6.69M	Buy	435,075 +67,575	+18%	+$1.21M	0.05%	386
2024 Q4	$8.1M	Buy	367,500 +183,000	+99%	+$3.33M	0.06%	339
2024 Q3	$3.32M	Buy	184,500 +134,500	+269%	+$2.35M	0.02%	548
2024 Q2	$813K	Buy	50,000 +18,000	+56%	+$277K	0.01%	818
2024 Q1	$452K	Hold	32,000	–	–	﹤0.01%	901
2023 Q4	$334K	Hold	32,000	–	–	﹤0.01%	940
2023 Q3	$326K	Sell	32,000 -9,200	-22%	-$85.7K	﹤0.01%	956
2023 Q2	$310K	Sell	41,200 -1,000	-2%	-$8.11K	﹤0.01%	971
2023 Q1	$373K	Sell	42,200 -800	-2%	-$7.91K	﹤0.01%	958
2022 Q4	$392K	Sell	43,000 -11,000	-20%	-$96K	﹤0.01%	976
2022 Q3	$436K	Sell	54,000 -3,000	-5%	-$26.5K	﹤0.01%	1007
2022 Q2	$429K	Sell	57,000 -2,000	-3%	-$17.4K	﹤0.01%	1044
2022 Q1	$554K	Hold	59,000	–	–	﹤0.01%	1025
2021 Q4	$473K	Sell	59,000 -4,000	-6%	-$36.1K	﹤0.01%	1096
2021 Q3	$614K	Sell	63,000 -6,020	-9%	-$56.4K	﹤0.01%	1012
2021 Q2	$683K	Sell	69,020 -3,000	-4%	-$31.8K	﹤0.01%	987
2021 Q1	$831K	Buy	+72,020	New	+$826K	0.01%	940
2019 Q3	–	Sell	-13,000	Closed	-$120K	–	1136
2019 Q2	$120K	Buy	+13,000	New	+$157K	﹤0.01%	1102
2017 Q4	–	Sell	-20,000	Closed	-$352K	–	1124
2017 Q3	$352K	Buy	20,000 +5,000	+33%	+$113K	﹤0.01%	1036
2017 Q2	$498K	Sell	15,000 -40,000	-73%	-$1.24M	﹤0.01%	1006
2017 Q1	$1.76M	Hold	55,000	–	–	0.01%	813
2016 Q4	$1.99M	Hold	55,000	–	–	0.01%	784
2016 Q3	$2.53M	Hold	55,000	–	–	0.02%	730
2016 Q2	$2.76M	Hold	55,000	–	–	0.02%	715
2016 Q1	$2.94M	Buy	55,000 +5,000	+10%	+$293K	0.02%	680
2015 Q4	$3.28M	Buy	50,000 +35,000	+233%	+$2.16M	0.02%	633
2015 Q3	$847K	Hold	15,000	–	–	0.01%	879
2015 Q2	$887K	Sell	15,000 -5,000	-25%	-$308K	﹤0.01%	892
2015 Q1	$1.25M	Hold	20,000	–	–	0.01%	846
2014 Q4	$1.15M	Sell	20,000 -1,000	-5%	-$55.7K	0.01%	865
2014 Q3	$1.13M	Hold	21,000	–	–	0.01%	865
2014 Q2	$1.1M	Buy	21,000 +6,000	+40%	+$307K	0.01%	861
2014 Q1	$793K	Hold	15,000	–	–	﹤0.01%	893
2013 Q4	$601K	Hold	15,000	–	–	﹤0.01%	923
2013 Q3	$567K	Hold	15,000	–	–	﹤0.01%	915
2013 Q2	$588K	Buy	+15,000	New	+$584K	﹤0.01%	898

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Gabelli Funds's TEVA Position: Q2 2026 in Review

Gabelli Funds reduced its Teva Pharmaceuticals (TEVA) stake by 0.42% in Q2 2026, selling an estimated $46.6K and leaving 331,500 shares worth $11.2M. The position accounts for 0.07% of the portfolio, ranked #318.

Gabelli Funds first reported a position in TEVA in Q2 2013 and has held it in 41 quarters since. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Gabelli Funds held 331,500 shares of Teva Pharmaceuticals worth $11.2M as of Q2 2026.
Gabelli Funds sold 1,400 Teva Pharmaceuticals shares in Q2 2026, an estimated $46.6K.
Teva Pharmaceuticals made up 0.07% of Gabelli Funds's portfolio in Q2 2026, its #318 holding.
Gabelli Funds first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Gabelli Funds's 13F filing for Q2 2026, filed 12 Aug 2026.